Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A F List

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|May 1, 1991
Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotypeA F List, C M Spier, A Cline, et al.
Anti-Cancer Drugs|June 1, 1991
A phase I trial of 14-day continuous intravenous infusion mitoxantroneW H Kreisle, D S Alberts, A F List, et al.
Annals of Internal Medicine|July 1, 1986
Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testisD C Doll, A F List, F A Greco, et al.
Blood|February 27, 2001
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromesW T Bellamy, L Richter, D Sirjani, et al.
Leukemia Research|February 1, 1996
Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)A Samdani, U Vijapurkar, M A Grimm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 1990
Primary brain lymphoma in the immunocompetent host: relation to Epstein-Barr virusA F List, J P Greer, J P Cousar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemiaA F List, C Spier, J Greer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintainedC W Taylor, L M Wang, A F List, et al.
Leukemia|December 22, 2012
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysisA Kuendgen, M Lauseker, A F List, et al.
Leukemia|October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDSA F List, J M Bennett, M A Sekeres, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|May 1, 1991
Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotypeA F List, C M Spier, A Cline, et al.
Anti-Cancer Drugs|June 1, 1991
A phase I trial of 14-day continuous intravenous infusion mitoxantroneW H Kreisle, D S Alberts, A F List, et al.
Annals of Internal Medicine|July 1, 1986
Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testisD C Doll, A F List, F A Greco, et al.
Blood|February 27, 2001
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromesW T Bellamy, L Richter, D Sirjani, et al.
Leukemia Research|February 1, 1996
Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML)A Samdani, U Vijapurkar, M A Grimm, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 1, 1990
Primary brain lymphoma in the immunocompetent host: relation to Epstein-Barr virusA F List, J P Greer, J P Cousar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1993
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemiaA F List, C Spier, J Greer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintainedC W Taylor, L M Wang, A F List, et al.
Leukemia|December 22, 2012
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysisA Kuendgen, M Lauseker, A F List, et al.
Leukemia|October 24, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDSA F List, J M Bennett, M A Sekeres, et al.
Pageof 10